FDA Expands OTC Naloxone Access: What It Means for Patients and Pharmacists

Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about the FDA's expansion of over-the-counter naloxone access, remaining barriers to availability, and the critical role pharmacists play in overdose prevention and patient education.

Newman explains that the availability of OTC naloxone sends an important message about the medication’s safety and may help improve access by simplifying purchasing and distribution processes for community organizations. However, she notes that cost remains a significant barrier, as many individuals at risk for overdose are not purchasing naloxone directly from pharmacies or retail stores. Instead, much of the naloxone used in communities continues to be distributed through nonprofit organizations, health departments, and other community-based programs.

The discussion also highlights ongoing challenges to naloxone access, particularly in rural areas where distribution sites may be limited. Newman describes innovative community-based approaches in Washington state, including naloxone vending machines and repurposed newspaper boxes that provide easy public access to overdose reversal kits. She emphasizes the importance of ensuring that individuals know where to obtain naloxone, understand how to use it, and educate friends and family members about overdose response.

In addition, Newman discusses the critical role pharmacists can play in expanding access and improving overdose prevention efforts. She explains that pharmacists are uniquely positioned to identify patients at increased risk for overdose, including individuals receiving opioid prescriptions or medications for opioid use disorder such as buprenorphine. Through patient counseling, education, and community outreach, pharmacists can help increase awareness of naloxone and encourage preparedness among patients and their support networks.

Although naloxone remains a vital tool for reversing opioid overdoses, Newman emphasizes that it represents only one component of a broader strategy that must also include evidence-based treatments such as buprenorphine and methadone to reduce overdose-related mortality.